Last reviewed · How we verify
Sars Cov 2 infection
At a glance
| Generic name | Sars Cov 2 infection |
|---|---|
| Sponsor | Novafem |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) (PHASE1)
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain (NA)
- A Longitudinal Study of COVID-19 Sequelae and Immunity
- Impact of COVID-19 Pandemic on Single-stage Laparoscopic Cholecystectomy and Laparoscopic Common Bile Duct Exploration Service
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sars Cov 2 infection CI brief — competitive landscape report
- Sars Cov 2 infection updates RSS · CI watch RSS
- Novafem portfolio CI